Hapvida Participacoes e Investimentos SA
BOVESPA:HAPV3

Watchlist Manager
Hapvida Participacoes e Investimentos SA Logo
Hapvida Participacoes e Investimentos SA
BOVESPA:HAPV3
Watchlist
Price: 16.04 BRL -0.62%
Market Cap: 8.1B BRL

Hapvida Participacoes e Investimentos SA
Investor Relations

Hapvida Participações e Investimentos SA stands as a prominent player in Brazil's healthcare landscape, weaving an intricate tapestry of innovation and tradition in the nation's burgeoning private health sector. Headquartered in Fortaleza, this integrated health company began its journey in 1993. Initially, it was a small hospital that sought to address Brazil’s growing demand for accessible and comprehensive healthcare services. Over the years, Hapvida expanded its horizons by building a vast network that now includes hospitals, clinics, and laboratories scattered strategically across the country. This robust infrastructure forms the backbone of its operations, allowing the company to provide a seamless patient experience from diagnosis to aftercare. Driven by a commitment to technology, Hapvida harnesses advanced medical platforms to streamline its services, ensuring efficiency and cost-effectiveness, thus reinforcing its reputation as a leader in value-based healthcare.

Hapvida’s business model thrives on vertical integration, a strategic choice that aligns various facets of healthcare delivery under one umbrella. This model not only enhances operational control but also reduces costs—a critical factor in a diverse and complex market like Brazil. By owning and managing its entire network of facilities, Hapvida enjoys significant bargaining power, enabling it to offer competitive pricing for its health plans. The company’s revenue is largely generated from these health insurance plans, which are marketed to individuals and corporate clients seeking affordable private healthcare options. Simultaneously, its owned hospitals and clinics serve as revenue streams through direct patient care services. Through this dual approach, Hapvida not only ensures steady income but also fortifies its standing as a trusted provider of health services, catering to millions and redefining the standards of private healthcare in Brazil.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 13, 2025
AI Summary
Q3 2025

Network Expansion: Hapvida opened seven new hospitals and 25 outpatient clinics in 2025, adding around 1,000 new beds, with half already operational.

Short-Term Margin Pressure: The ramp-up of new units and higher service usage led to increased fixed costs and a reported MLR of 75.2%, above seasonal patterns.

Customer Satisfaction: Significant improvements were seen in customer service metrics, with complaint rates (NEPs) down 40% since early 2024 and faster emergency room response times.

Membership Growth: Membership grew by 12,000 in Q3, lower than expected, with strong corporate gains but weaker SME and affinity group performance, especially in São Paulo.

Cost Control Initiatives: The company is renegotiating with its accredited network, standardizing care practices, and launching a new pathology center to cut costs.

Pricing & Outlook: Average ticket adjustments are expected to be around 10% for the year, with no major changes planned; management expects margin recovery and benefit from network expansion in 2026.

Financial Performance: Adjusted EBITDA was BRL 746 million, adjusted net income BRL 338 million, and free cash flow was negative BRL 52 million, impacted by higher costs and provisions.

Key Financials
MLR
75.2%
Adjusted EBITDA
BRL 746 million
Adjusted Net Income
BRL 338 million
Free Cash Flow
-BRL 52 million
Membership Growth
12,000 members (Q3)
Occupancy Rate (selected regions)
85%
Fixed Costs New Units (Q3)
BRL 80 million
Average Ticket (Price Adjustment)
Around 10%
Contingencies over Revenue
3.2%
Provision Coverage for Deposits
104%
Leverage
1x EBITDA
Earnings Call Recording
Other Earnings Calls

Management

Mr. Jorge Fontoura Pinheiro Koren de Lima
Statutory CEO, Member of Board of Executive Officers & Director
No Bio Available
Mr. Luccas Augusto Adib
Statutory Chief Financial & Investor Relations Officer and Member of Executive Board
No Bio Available
Alain Benvenuti
Statutory COO & Member of Board of Executive Officers
No Bio Available
Mr. Igor Macedo Faco
Statutory Chief Legal Officer & Member of Board of Executive Officers
No Bio Available
Gustavo Henrique Zacharias Ribeiro
Statutory Chief of Institutional Relations Officer & Member of Board of Executive Officers
No Bio Available
Mr. Gilson Ramos
Accounting Director
No Bio Available
Kleber Linhares
Vice President of Technology & Innovation
No Bio Available
João Carlos Schneider
Corporate Director of Audit, Risks & Compliance
No Bio Available
Jaqueline Sena
Vice President of Dental & Marketing
No Bio Available
Eliana Vieira
Vice President of Human Resources
No Bio Available

Contacts

Address
CEARA
Fortaleza
Avenida Heraclito Graca n 406, Centro
Contacts